This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bjelfman, C. Articles by Rane, A. Search for Related Content PubMed PubMed Citation Articles by Bjelfman, C. Articles by Rane, A.

Differential Gene Expression of Steroid 5-Reductase 2 in Core Needle Biopsies from Malignant and Benign Prostatic Tissue¹

Departments of Clinical Pharmacology (C.B., T.G.S., A.R.), Urology (E.B., B.J.N.), and Pathology (L.E.), University Hospital, Uppsala, Sweden; Molecular Biology, Biomedical Centre (T.U.), Uppsala, Sweden; and Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas, Southwestern Medical Center (S.A.), Dallas, Texas

Address all correspondence and requests for reprints to: Anders Rane, Department of Clinical Pharmacology, University Hospital, S-751 85 Uppsala, Sweden. E-mail: Anders.Rane{at}klinfarm.uu.se

Androgens are implicated in the development of prostate cancer (CAP) and benign prostate hyperplasia. The conversion of testosterone to the more potent metabolite dihydrotestosterone by prostate-specific steroid 5-reductase type 2 (5-red2) is a key mechanism in the action of androgens in the prostate and is important in the promotion and progression of prostate diseases. Manipulation of the turnover of androgens is thus fundamental in the pharmacological treatment strategy.

We have developed a sensitive solution hybridization method for quantification of the gene expression of 5-red2 in core needle biopsies of the prostate. The 5-red2-specific messenger RNA (mRNA) levels were measured in 50 human prostate transrectal ultrasound-guided core biopsies obtained from 31 outpatients (median age 72, range 57–88 yr) undergoing biopsy for diagnostic purposes. Significant differences were observed in the gene expression of 5-red2 between cancerous and noncancerous tissue. In the 14 biopsies judged cancerous, the median 5-red mRNA levels were 3.5 amol/ng total RNA compared with 12.0 amol/ng total RNA in the biopsies showing no cancer (P = 0.0018). The median 5-red2 mRNA level in noncancerous tissue was thus 3.4 times higher than in the cancerous specimens.

This article has been cited by other articles:

				R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al. Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437. [Abstract] [Full Text] [PDF]

				T. G. Söderström, C. Bjelfman, E. Brekkan, B. Ask, L. Egevad, B. J. Norlén, and A. Rane Messenger Ribonucleic Acid Levels of Steroid 5{{alpha}}-Reductase 2 in Human Prostate Predict the Enzyme Activity J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 855 - 858. [Abstract] [Full Text]